11/14/2023 0 Comments Insulin unit calculator![]() In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. Lung Cancer: In clinical trials, 2 cases of lung cancer were observed in patients exposed to AFREZZA while no cases were reported for the comparators. If symptoms persist, discontinue AFREZZA. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. In patients who have a decline of ≥20% in FEV 1 from baseline, consider discontinuing AFREZZA. Assess pulmonary function with spirometry at baseline, after the first 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. In clinical trials excluding patients with chronic lung disease and lasting up to 2 years, AFREZZA-treated patients experienced a small (40 mL) but greater FEV 1 decline than comparator-treated patients. ![]() ![]() Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia.ĭecline in Pulmonary Function: AFREZZA causes a decline in lung pulmonary function over time as measured by FEV 1. Patients and caregivers should be educated to recognize and manage hypoglycemia. Hypoglycemia can happen suddenly, and symptoms may differ across patients and change over time in the same patient. Hypoglycemia can impair concentration ability and reaction time this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia: Hypoglycemia is the most common adverse reaction associated with insulins, including AFREZZA. For patients with type 2 diabetes, dosage modifications of concomitant oral antidiabetic treatment may need to be needed. These changes should be made under close medical supervision and the frequency of blood glucose monitoring should be increased. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Hypoglycemia or Hyperglycemia with Changes in Insulin Regimen: Glucose monitoring is essential for patients receiving insulin therapy. Do not use in patients with chronic lung disease such as asthma or COPD. Before initiating therapy, evaluate all patients with a medical history, physical examination, and spirometry (FEV 1) to identify potential underlying lung disease. Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV 1) to identify potential lung disease in all patients.ĪFREZZA is contraindicated: during episodes of hypoglycemia, in patients with chronic lung disease (such as asthma or chronic obstructive pulmonary disease ) because of the risk of acute bronchospasm, and in patients with hypersensitivity to regular human insulin or any of the excipients in AFREZZA.Īcute Bronchospasm: In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |